BILLIONTOONE INC. A O.N.

BTIG confirms BillionToOne as its top pick in the diagnostics sector, lowers the price target from $142 to $130, citing an 11.5x multiple on 2028 revenue expectations. BillionToOne reported Q2 revenue of $109.4m (+64% y/y) and reiterated full‑year guidance of $450–465m, but the stock fell 28% in after‑hours trading. The release was marked by declining true‑ups, a one‑time receivable delay of over $10m with a major payer, product updates (NorthStar Select expansion, UNITY roll‑out) and an expanded sales team. » More on de.investing.com

BillionToOne reported Q1 2026 revenue of $108.4m (+84% yoy) and earnings per share of $0.34, after a loss in the prior year. Gross margin was 73% and operating income turned to a profit of $17.8m. The new prenatal diagnostic product UNITY Confirm is expected to strengthen the portfolio, while the oncology business saw strong growth. After the results, the stock climbed about 16% in after-hours trading; management sees further EPS growth in coming quarters. » More on de.investing.com

BillionToOne posted Q1 2026 revenue of $108.4 million (+84% year/year), a gross margin of 73%, a GAAP operating margin of 16% and an adjusted EBITDA margin of 24%. Test volume rose 44% to 188,000 tests, the average selling price was $571, and the annualized revenue run rate is now $434 million. Management highlighted Unity Confirm as a new non-invasive prenatal diagnostic product, secured Anthem in-network status and raised the full-year guidance to $450–465 million. Liquidity stood at $537.5 million; risks remain around clinical timelines, reimbursement dynamics and competition. » More on de.investing.com